Nomenclature
CAS number: 77181-69-2
1-β-
d-Arabinofuranosyl-5-[(1
E)-2-bromoethenyl]-2,4(1
H,3
H)-pyrimidinedione; 1-β-
d-arabinofuranosyl-(
E)-5-(2-bromovinyl)uracil; 5-bromovinyl-araU; brovavir; BV-araU; BVAU; YN-72; SQ-32756; Usevir (Yamasa Shoyu).
C
11H
13BrN
2O
6; mol wt 349.13.
C 37.84%, H 3.75%, Br 22.89%, N 8.02%, O 27.50%.
Description and references
Orally active antiviral agent; inhibits viral
DNA synthesis. Prepn: H. Machida, S. Sakata, EP 31128; eidem, US 4386076 (1981, 1983 both to Yamassa Shoyu); S. Sakata et al., Nucleic Acids Symp. Ser. 8, s39 (1980); R. Busson et al., ibid. 9, 49 (1981). Antiviral
activity and toxicity: H. Machida, S. Sakata, Antiviral Res. 4, 135 (1984). Mechanism of
action studies: T. Yokota et al., Mol. Pharmacol. 36, 312 (1989); H. Machida, Adv. Exp. Med. Biol. 278, 255
(1990). Clinical trial in herpes zoster infection: M. Niimura, ibid. 267.
Properties
mp 182° (Sakata, 1980); also reported as white crystals from ethanol, mp 195-200° (dec) (Machida,
Sakata, 1983). [α]D25 +0.5° (1N NaOH). LD50 in mice (mg/kg): ≈3300 i.p.; >5000 s.c.; >10000 orally (Machida, Sakata, 1984).Therapeutic Category
Antiviral.
Keywords
Antiviral; Nucleosides/Nucleotides